Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics
GET POWR RATINGS... FREE!
MRSN POWR Grades
- Momentum is the dimension where MRSN ranks best; there it ranks ahead of 47.4% of US stocks.
- MRSN's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
- MRSN ranks lowest in Growth; there it ranks in the 4th percentile.
MRSN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for MRSN is 0 -- better than merely 6.23% of US stocks.
- MRSN's price/sales ratio is 14,336; that's higher than the P/S ratio of 99.74% of US stocks.
- As for revenue growth, note that MRSN's revenue has grown -97.4% over the past 12 months; that beats the revenue growth of merely 0.92% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Mersana Therapeutics Inc, a group of peers worth examining would be CALT, TFFP, VNRX, CVM, and ARDS.
- MRSN's SEC filings can be seen here. And to visit Mersana Therapeutics Inc's official web site, go to www.mersana.com.
MRSN Valuation Summary
- MRSN's EV/EBIT ratio is -6.3; this is 121.5% lower than that of the median Healthcare stock.
- Over the past 51 months, MRSN's price/sales ratio has gone up 22705.9.
- Over the past 51 months, MRSN's price/sales ratio has gone up 22705.9.
Below are key valuation metrics over time for MRSN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MRSN | 2021-08-31 | 22718.2 | 5.1 | -7.9 | -6.3 |
| MRSN | 2021-08-30 | 22279.5 | 5.0 | -7.7 | -6.1 |
| MRSN | 2021-08-27 | 21218.2 | 4.8 | -7.4 | -5.7 |
| MRSN | 2021-08-26 | 19213.6 | 4.3 | -6.7 | -5.0 |
| MRSN | 2021-08-25 | 19277.3 | 4.3 | -6.7 | -5.1 |
| MRSN | 2021-08-24 | 18804.5 | 4.2 | -6.5 | -4.9 |
MRSN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRSN has a Quality Grade of D, ranking ahead of 23.99% of graded US stocks.
- Service Unavailable
- ARNA, EYEG, and AGTC are the stocks whose asset turnover ratios are most correlated with MRSN.
The table below shows MRSN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | 1 | -19.265 |
| 2021-03-31 | 0.003 | 1 | -11.244 |
| 2020-12-31 | 0.003 | 1 | -4.878 |
| 2020-09-30 | 0.004 | 1 | -3.132 |
| 2020-06-30 | 0.011 | 1 | -2.130 |
| 2020-03-31 | 0.009 | 1 | -2.198 |
MRSN Price Target
For more insight on analysts targets of MRSN, see our MRSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.67 | Average Broker Recommendation | 1.29 (Strong Buy) |
MRSN Stock Price Chart Interactive Chart >
MRSN Price/Volume Stats
| Current price | $8.45 | 52-week high | $29.09 |
| Prev. close | $8.47 | 52-week low | $8.16 |
| Day low | $8.35 | Volume | 100,102 |
| Day high | $8.61 | Avg. volume | 797,156 |
| 50-day MA | $10.57 | Dividend yield | N/A |
| 200-day MA | $14.77 | Market Cap | 606.39M |
Mersana Therapeutics, Inc. (MRSN) Company Bio
Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Latest MRSN News From Around the Web
Below are the latest news stories about Mersana Therapeutics Inc that investors may wish to consider to help them evaluate MRSN as an investment opportunity.
Hedge Funds Are Betting On Mersana Therapeutics, Inc. (MRSN)In this article we will analyze whether Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […] |
Mersana Highlights New Preclinical Data For XMT-2056 Cancer SettingsMersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference. XMT-2056 is an Immunosynthen STING-agonist ADC candidate, targeting an epitope of human epidermal growth factor receptor 2 (HER2). Previously, across multiple targets and models, Immunosynthen ADCs stimulated the innate immune system in a targeted manner in both tumor cells and tumor-resident myeloid cells. In new head-to-head preclin |
Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsPreclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in head-to-head studies than trastuzumab-TLR7/8 agonist ADC and small-molecule systemically-administered STING agonist benchmarksXMT-2056 targets a novel epitope of HER2 with differentiated binding from trastuzumab and pertuzumab, potentially allowing for broad combinability with approved and investigational |
Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsCAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International |
Is Mersana Stock a Buy Right Now? This Is What You Need to KnowIf you’re after big returns, the biotech sector is your go-to destination, although investors should proceed with caution as instead of mighty gains a portfolio can also dwindle alarmingly if a company in the highly volatile sector fails to deliver the goods. Which is what investors evidently felt after taking in the latest news out of Mersana Therapeutics (MRSN) HQ. On Friday, shares shed about 40% of their value after the company provided a clinical trial update. The company disclosed interim |
MRSN Price Returns
| 1-mo | -11.89% |
| 3-mo | -28.99% |
| 6-mo | -47.25% |
| 1-year | -52.77% |
| 3-year | 12.82% |
| 5-year | N/A |
| YTD | -68.25% |
| 2020 | 364.40% |
| 2019 | 40.44% |
| 2018 | -75.17% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching MRSN
Want to do more research on Mersana Therapeutics Inc's stock and its price? Try the links below:Mersana Therapeutics Inc (MRSN) Stock Price | Nasdaq
Mersana Therapeutics Inc (MRSN) Stock Quote, History and News - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...